Antibodies directed against ICOS and uses thereof
US11180556B2 · kind B2 · utility
0Cited by
6References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 23, 2018 |
| Grant date | Nov 23, 2021 |
| Priority date | — |
| Expiry date | Jul 27, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFNγ production, induce CD4− T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.